Drug Trial Radar · NCT06079398
A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Years of Age) With Achondroplasia
Last checked: Nov 20, 2026Latest source record: Apr 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
72
Planned (sponsor's estimate)
Start
Jan 23, 2024
Primary completion
Dec 2027
Study completion Dec 2028
Sponsor
- Lead sponsor
- Ascendis Pharma A/SIndustry
- Sponsor type
- Industry
- First posted
- Oct 12, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 0 years, up to 2 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial is a Phase 2, multicenter, double-blind, randomized (ratio 2:1 TransCon CNP vs. placebo), placebo-controlled trial, designed to evaluate the safety, tolerability, and efficacy of 100 μg CNP/kg of Navepegritide (TransCon CNP) administered SC once-weekly for 52 weeks in infants with genetically verified heterozygous ACH, aged 0 to \< 2 years at the time of randomization.
Conditions
- Achondroplasia
Interventions
NavepegritideDrug
Once-weekly subcutaneous injection of 100 µg/kg Navepegritide
Placebo for NavepegritideDrug
Once-weekly subcutaneous injection of 100 µg/kg placebo for Navepegritide
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the safety and tolerability of NavepegritideTime frame: 52 weeks
- To evaluate the effect of Navepegritide on growthTime frame: 52 weeks
Locations
18 sites in 15 countries. Site status is shown where the registry gives one.
Ascendis Investigational Site
Saint Paul, Minnesota · Recruiting
Ascendis Investigational Site
Houston, Texas · Recruiting
Ascendis Investigational Site
Madison, Wisconsin · Recruiting
Ascendis Investigational Site
Parkville, Australia · Recruiting
Ascendis Investigational Site
Linz, Austria · Recruiting
Ascendis Investigational Site
Montreal, Canada · Recruiting
Ascendis Investigational Site
Copenhagen, Denmark · Recruiting
Ascendis Investigational Site
Helsinki, Finland · Recruiting
Ascendis Investigational Site
Paris, France · Recruiting
Ascendis Investigational Site
Berlin, Germany · Recruiting
Ascendis Investigational Site
Cologne, Germany · Recruiting
Ascendis Investigational Site
Dublin, Ireland · Recruiting
Ascendis Investigational Site
Milan, Italy · Recruiting
Ascendis Investigational Site
Auckland, New Zealand · Recruiting
Ascendis Investigational Site
Oslo, Norway · Recruiting
Ascendis Investigational Site
Coimbra, Portugal · Recruiting
Ascendis Investigational Site
Stockholm, Sweden · Recruiting
Ascendis Investigational Site
London, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.